Features

Which new market entrants should be on the industry’s radar in 2025?  What new products, recently or expected to launch in 2025, show blockbuster potential? A look at the leading blockbuster contenders.    

Under a new US Administration, will drug-pricing reforms that call for the US government to negotiate prices for certain drugs continue? Will these reforms stay in play, and which products may be affected?

How did the industry fare with new drug approvals in 2023? What new drugs were approved by FDA and were approvals in pace with prior years? What was the mix between small molecules and biologics, and which companies and products made the mark? DCAT Value Chain Insights sums it up.

Applications are closing Wednesday February 5 for the DCAT Member Company Announcement Forum, a much-anticipated event at DCAT Week in which senior executives from DCAT Member Companies highlight major news announcements covering expansions, M&A, and other key strategic developments.

What are the key issues shaping the market for small-molecule drugs and related trends in manufacturing? An industry roundtable of senior executives share their perspectives on what is driving the market.

What were the biologic-based drugs approved by FDA’s Center for Drug Evaluation and Research in 2024? Which companies and products crossed the regulatory finish line and how do they fit in the market?

How is innovation inspiring and fueling the transformation of the bio/pharma industry?DCAT’s conference and networking event, Expedition Pharma: Innovation from a Patient-First Perspective, being held June 4–5, 2025, in Lugano, Switzerland, will provide key insights.  

How do small-molecule drugs rank in the strategy of the bio/pharmaceutical majors? What are the leading products from a revenue perspective, and what are key developments on a commercial and pipeline basis? DCAT Value Chain Insights looks at what may be in store for 2025.

What are key issues shaping the market for bio/pharmaceutical outsourcing in the coming year? DCAT Value Chain Insights takes an inside look into the market drivers, trends, and key activity shaping the CDMO/CMO market.

Deal-making by the large pharma companies in antibody drug conjugates (ADCs) to build their in product portfolios in oncology has been on the upsurge, but will the ADC wave continue in 2025? A look at recent deals and what may lie ahead.